Srikumar Sahasranaman
About Srikumar Sahasranaman
Srikumar Sahasranaman is the Vice President of Clinical Pharmacology at BeiGene in Cambridge, Massachusetts. He has extensive experience in clinical pharmacology, having held senior roles at Genentech, Novartis, and Sanofi, and has a strong educational background in pharmacy and pharmacology.
Company
Srikumar Sahasranaman currently works at BeiGene as Vice President, Clinical Pharmacology. BeiGene is located in Cambridge, Massachusetts, United States. He has been with BeiGene since January 2017, bringing extensive experience in clinical pharmacology to the role.
Title
Srikumar Sahasranaman holds the title of Vice President, Clinical Pharmacology. In this senior leadership role, he oversees clinical pharmacology strategies and operations at BeiGene.
Educational Background
Srikumar Sahasranaman has a robust educational background in pharmacy and pharmacology. He earned a Doctor of Philosophy (PhD) from the University of Florida, which he attended from 2000 to 2004. Prior to that, he completed a Master of Science (MS) in Pharmacy from the National University of Singapore between 1998 and 2000. He also holds a Bachelor of Pharmacy (BPharm) from Birla Institute of Technology and Science, Pilani, where he studied from 1993 to 1997.
Professional Experience
Srikumar Sahasranaman has an extensive professional background in clinical pharmacology. He worked at Genentech as Group Leader and Senior Scientist, Clinical Pharmacology, from 2010 to 2016 in South San Francisco, California. Before that, he was employed at Novartis as Expert Pharmacokineticist from 2006 to 2010 in Basel, Switzerland, and at Sanofi as Senior Research Investigator from 2004 to 2006 in Aquitaine, France. Earlier in his career, he completed a two-month internship at the FDA in Silver Spring, Maryland, in 2003.
International Work Experience
Srikumar Sahasranaman's career is marked by significant international experience. He has worked in Switzerland and France, holding senior pharmacology positions at Novartis and Sanofi respectively, before moving to the United States. This international expertise has contributed to his comprehensive understanding of global pharmacological practices and standards.